Devyser today announces the appointment of Torben Thölix as Chief Commercial Officer (CCO). Torben will lead Devyser's global commercial organization and join the executive management team, reporting to CEO, Jan Wahlström. Torben will begin transitioning into the role during September and assume the position full-time on October 1.
Torben brings more than 20 years of international commercial leadership experience in life sciences and healthcare. He joins Devyser from Mercodia AB, where, as CCO, he contributed to the two strongest years in the company’s 35-year history, including its recognition as a DI Gasell company in 2025. Previously, he served as CCO at BICO and Global Sales Director at Biolin Scientific. Earlier in his career, Torben held senior commercial leadership positions at companies including Tobii and Circassia Pharmaceuticals, with responsibilities spanning the US, Europe, the Middle East and Asia-Pacific.
“We continue to grow across both our direct sales and distributor markets, making strong commercial execution increasingly important. Torben has a proven ability to scale commercial organizations and deliver sustainable growth in complex international life science markets. His experience and leadership will be highly valuable as we strengthen our global commercial capabilities and expand our market presence,” says Jan Wahlström, CEO, Devyser.
“Devyser has built a strong commercial momentum, supported by a growing product portfolio and strategic partnerships with Thermo Fisher Scientific and Illumina. I look forward to working with the team to build on this foundation, accelerate sustainable global growth and further strengthen Devyser’s commercial position. The US represents a particularly significant opportunity, and I am excited to contribute to the company’s continued international expansion,” says Torben Thölix.
